Bernard Escudier1, Vincent Molinie2, Sergio Bracarda3, Pablo Maroto4, Cezary Szczylik5, Paul Nathan6, Sylvie Negrier7, Claudia Weiss8, Camillo Porta9, Viktor Grünwald10, Laurence Albiges11. 1. Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France. Electronic address: escudier@gustaveroussy.fr. 2. Laboratoire d'Anatomie et Cytologie Pathologiques, CHU La Meynard, BP 632, 97261, Fort-de-France, Cedex, France. 3. Ospedale San Donato Medical Oncology, San Donato Hospital, Istituto Toscano Tumori, Via Pietro Nenni, 20 52100, Arezzo, Italy. 4. Oncology Department, Hospital de la Santa Creu, Sant Pau Maria Claret, 167, Barcelona, Spain. 5. Department of Oncology, Military Institute of Medicine, Szaserow 128, 04-141, Warsaw, Poland. 6. Mount Vernon Cancer Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK. 7. University of Lyon, Centre Leon Berard, 28 Rue Laennec, Lyon, France. 8. Novartis Pharma GmbH, Roonstr. 25, D-90429, Nuernberg, Germany. 9. IRCCS San Matteo University Hospital Foundation, Medical Oncology, Piazzale C. Golgi, 19, 27100, Pavia, Italy. 10. Clinic for Haematology, Haemostaseology, and Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany. 11. Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France.
Abstract
BACKGROUND: Papillary histology accounts for 10-15% of renal cell carcinoma (RCC), and treatment options for patients with this subtype are limited. The RAPTOR (RAD001 in Advanced Papillary Tumor Program in Europe; ClinicalTrials.gov, NCT00688753) study evaluated first-line everolimus in patients with papillary metastatic RCC (mRCC). METHODS: This phase 2 trial enrolled previously untreated patients with type 1 or type 2 papillary mRCC. Papillary histology was confirmed by central review and was performed for every patient. Patients received oral everolimus 10 mg once daily until disease progression or unacceptable toxicity. The primary end-point was progression-free survival (PFS) rate at 6 months among the first 44 patients of the per protocol (PP) population. Secondary end-points included PFS, tumour response, overall survival (OS), and safety. FINDINGS: Analysis sets included safety (N = 92; 100%), intent-to-treat (ITT) (n = 88), and PP populations (n = 46). In the safety population, most patients were men (78%) and the mean age was 60 years (range 23-84). Papillary histology was confirmed in 78% of patients (type 1, 32%; type 2, 64%; missing information, 4%). PFS rate at 6 months was 34% (80% confidence interval [CI] 25-45). In the ITT population, median PFS was 4.1 months (95% CI 3.6-5.5), 65% of patients achieved stable disease, and median OS was 21.4 months (95% CI 15.4-28.4). Among patients with type 1 or type 2 histology, median PFS was 7.9 months (95% CI 2.1-11.0) and 5.1 months (95% CI 3.3-5.5), respectively, and median OS was 28.0 months (95% CI 7.6-not estimable) and 24.2 months (95% CI 15.8-32.8), respectively. Common grade >2 adverse events were asthenia (13%), anaemia (7%), and fatigue (5%). INTERPRETATION: Results of this large prospective study in papillary mRCC demonstrated that everolimus provides some clinical benefit to this patient population and highlight the need for central pathological review of this rare tumour. Copyright Â
BACKGROUND: Papillary histology accounts for 10-15% of renal cell carcinoma (RCC), and treatment options for patients with this subtype are limited. The RAPTOR (RAD001 in Advanced Papillary Tumor Program in Europe; ClinicalTrials.gov, NCT00688753) study evaluated first-line everolimus in patients with papillary metastatic RCC (mRCC). METHODS: This phase 2 trial enrolled previously untreated patients with type 1 or type 2 papillary mRCC. Papillary histology was confirmed by central review and was performed for every patient. Patients received oral everolimus 10 mg once daily until disease progression or unacceptable toxicity. The primary end-point was progression-free survival (PFS) rate at 6 months among the first 44 patients of the per protocol (PP) population. Secondary end-points included PFS, tumour response, overall survival (OS), and safety. FINDINGS: Analysis sets included safety (N = 92; 100%), intent-to-treat (ITT) (n = 88), and PP populations (n = 46). In the safety population, most patients were men (78%) and the mean age was 60 years (range 23-84). Papillary histology was confirmed in 78% of patients (type 1, 32%; type 2, 64%; missing information, 4%). PFS rate at 6 months was 34% (80% confidence interval [CI] 25-45). In the ITT population, median PFS was 4.1 months (95% CI 3.6-5.5), 65% of patients achieved stable disease, and median OS was 21.4 months (95% CI 15.4-28.4). Among patients with type 1 or type 2 histology, median PFS was 7.9 months (95% CI 2.1-11.0) and 5.1 months (95% CI 3.3-5.5), respectively, and median OS was 28.0 months (95% CI 7.6-not estimable) and 24.2 months (95% CI 15.8-32.8), respectively. Common grade >2 adverse events were asthenia (13%), anaemia (7%), and fatigue (5%). INTERPRETATION: Results of this large prospective study in papillary mRCC demonstrated that everolimus provides some clinical benefit to this patient population and highlight the need for central pathological review of this rare tumour. Copyright Â
Authors: Darren R Feldman; Yasser Ged; Chung-Han Lee; Andrea Knezevic; Ana M Molina; Ying-Bei Chen; Joshua Chaim; Devyn T Coskey; Samuel Murray; Satish K Tickoo; Victor E Reuter; Sujata Patil; Han Xiao; Jahan Aghalar; Arlyn J Apollo; Maria I Carlo; Robert J Motzer; Martin H Voss Journal: Cancer Date: 2020-09-25 Impact factor: 6.860
Authors: Andrey Soares; Fernando Sabino Marques Monteiro; Fernando Cotait Maluf; Diogo Assed Bastos; Denis Leonardo Jardim; André Deeke Sasse; Adriano Gonçalves E Silva; André P Fay; Diogo Augusto Rodrigues da Rosa; Evanius Wierman; Fabio Kater; Fabio A Schutz; Fernando Nunes Galvão de Oliveira; Igor Alexandre Protzner Morbeck; José Augusto Rinck; Karine Martins da Trindade; Manuel Caitano Maia; Vinicius Carrera Souza; Deusdedit Cortez Vieira da Silva Neto; Felipe de Almeida E Paula; Fernando Korkes; Gustavo Franco Carvalhal; Lucas Nogueira; Roni de Carvalho Fernandes; Rodolfo Borges Dos Reis; Wagner Eduardo Matheus; Wilson Francisco Schreiner Busato; Walter Henriques da Costa; Stênio de Cássio Zequi Journal: J Cancer Res Clin Oncol Date: 2020-05-14 Impact factor: 4.553
Authors: Rola M Saleeb; Mina Farag; Zsuzsanna Lichner; Fadi Brimo; Jenni Bartlett; Georg Bjarnason; Antonio Finelli; Fabio Rontondo; Michelle R Downes; George M Yousef Journal: Mol Oncol Date: 2018-08-23 Impact factor: 6.603
Authors: Michael Staehler; Peter J Goebell; Lothar Müller; Till-Oliver Emde; Natalie Wetzel; Lisa Kruggel; Martina Jänicke; Norbert Marschner Journal: Int J Cancer Date: 2019-11-22 Impact factor: 7.396